Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH 2 , Phe-D-Arg-Phe-Lys-NH 2 , or D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 .
1. A peptide conjugate comprising a therapeutic biological molecule conjugated to an aromatic-cationic peptide, wherein the aromatic-cationic peptide is 2′, 6′ dimethyl-Tyr-D-Arg-Phe-Lys-NH 2 , and wherein the therapeutic biological molecule is frataxin.
2. A peptide conjugate according to claim 1 , wherein the therapeutic biological molecule is conjugated to the aromatic-cationic peptide by a linker.
3. A peptide conjugate according to claim 1 , wherein the therapeutic biological molecule and aromatic-cationic peptide are chemically bonded.
4. A peptide conjugate according to claim 1 , wherein the therapeutic biological molecule and aromatic-cationic peptide are physically bonded.
5. A peptide conjugate according to claim 1 , wherein the aromatic-cationic peptide and the therapeutic biological molecule are linked using a labile linkage that is hydrolyzed in vivo to uncouple the aromatic-cationic peptide and the therapeutic biological molecule.
6. A peptide conjugate according to claim 5 , wherein the labile linkage comprises an ester linkage.